AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUL 82 min read$MGNX

MACROGENICS INC (MGNX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. mgnx-20260701 0001125345 FALSE 0001125345 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

Original reporting
SEC EDGAR 8-K
Published Jul 8, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$MGNX
Neutral
medium confidence
Mentioned
$MGNX
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MGNXNeutralLow
01

Why it matters

The only disclosed event is the resignation notice, effective September 1, 2026, with an explicit statement that it was not due to disagreements or company operational issues.

02

Market read

This is a governance update without new financial guidance, clinical data, or strategic transaction details.

03

What to watch

Traders may want to check whether Ferrante served on key committees (audit, compensation, nominating) and whether her replacement is announced in future filings.

Relevance 6/10Novelty 3/10Timing: after-hours, following the July 1 resignation notice and July 8 8-K filing

Background

The filing is an SEC Form 8-K under Item 5.02 for director/officer departure and related compensatory arrangements, dated from a July 1 notice.

Company-level read

Ticker impact

$MGNXNeutralMedium confidence
Context

MacroGenics disclosed Karen Ferrante’s resignation from the board, effective September 1, 2026, citing personal reasons.

Expected impact

Likely limited near-term impact unless investors later connect the departure to strategy, leadership, or committee changes.

Evidence & confidence

The 8-K is a primary-source executive/director departure notice with no disagreement with the company and no additional financial or strategic details.

Market effects

Sector

Minimal, as it is company-specific governance news with no sector-wide regulatory or clinical read-across.

Regional

None indicated; US-listed biotech governance update only.

Global

None indicated; no international operations or cross-border transaction details.

Counterpoint

What could challenge this read

Even with “personal reasons,” board departures can precede committee reshuffles or strategic pivots that may surface later in proxy materials.

Key entities

  • Director
    Karen Ferrante, M.D.

    Board member who provided notice of resignation effective September 1, 2026, for personal reasons.

  • Issuer
    MacroGenics, Inc.

    Company filing the 8-K reporting the director resignation under Item 5.02.

Read at source← All news

Related articles

AUG 11
$MGNXMed

MacroGenics stock rises on $10M Gilead option exercise

MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.

investing.com2 min
JUL 7
$MGNXMed

MACROGENICS INC (MGNX): Completion of Acquisition or Disposition of Assets

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and

SEC EDGAR 8-K4 min
JUL 2
$MGNXMedAI 8/10

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations – LiveNews.co.nz

Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ Rockville, Maryland GMP biologics drug-substance facility and a Frederick warehousing center for $122.5m via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics. Bora Biologics now has 20,000L SUB capacity across US sites and Taiwan.

livenews.co.nz3 min
JUL 2
$BORAYMedAI 8/10

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ GMP biologics drug-substance manufacturing operations in Rockville, MD, plus a Frederick, MD warehousing center, for $122.5M via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics and now has 20,000L US SUB capacity across Rockville and San Diego.

sina.com.hk5 min
JUL 2
$MGNXMed

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics (NASDAQ: MGNX) and Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) said the sale of MacroGenics’ GMP drug substance manufacturing operations to Bora has closed. Bora paid $122.5 million (before fees/expenses and post-closing adjustments). Bora assumed responsibility for Rockville, MD and Frederick, MD operations and hired about 140 employees; a supply agreement covers process development and drug substance production for MacroGenics’ pipeline needs.

manilatimes.net4 min
MACROGENICS INC (MGNX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers — alphai